TGFB1 and scleroderma: A wide range of drugs targeting the TGF-β signalling pathways are now available [69–73], and need to be tested for their ability to modulate the phenotypes of both these inherited scleroderma mimics but possibly also for efficacy in addition to anti-inflammatory medication in sporadic systemic sclerosis, given their overlapping pathomechanisms.